BioLineRx (BLRX) Tops Q3 EPS by 6c

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.02), $0.06 better than the analyst estimate of ($0.08).

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• UBS Downgrades Anhui Jianghuai Automobile Group Co Ltd (600418:CH) to Sell
• Halozyme prices $1.3B convertible notes offering due 2033